Related Experiment Video
Updated: Jan 17, 2026
Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
Published on: July 20, 2022
Impact of 20% Change in Vibration-Controlled Transient Elastography-Measured Liver Stiffness on Liver-Related
Konstantinos Ouranos1, Mark Michael1, Evangelia K Mylona2
1Department of Medicine, Houston Methodist Hospital, Houston, Texas.
Background & Aims:
The prognostic value of dynamic liver stiffness measurement (LSM) changes via vibration-controlled transient elastography in predicting liver-related events (LREs) for patients with compensated advanced chronic liver disease (cACLD) and no-cACLD remains unclear.
Methods:
We conducted a systematic review and meta-analysis of observational studies evaluating LRE risk in patients with ACLD and multiple LSMs. Clinically significant LSM changes were defined as: cACLD progressors (follow-up LSM [fuLSM] ≥20% increase with baseline LSM [bLSM] ≥10 kPa); no cACLD progressors (fuLSM ≥10 kPa, bLSM <10 kPa); cACLD regressors (fuLSM <10 kPa with bLSM ≥10 kPa or fuLSM ≥20% decrease with fuLSM <20 kPa). Relative risks (RRs) with 95% confidence intervals (CIs) were calculated.
Results:
Analysis of 24,557 patients from 7 studies revealed significant associations between dynamic LSM changes and LRE risk after a median follow-up of 52.8 months. cACLD progressors showed higher, although not statistically significant, LRE risk vs non-progressors (17.9% vs 6.5%; RR, 1.64; 95% CI, 0.56-4.81). No-cACLD progressors demonstrated significantly increased LRE risk compared with non-progressors (5.7% vs 0.4%; RR, 6.02; 95% CI, 4.22-8.59). Conversely, cACLD regressors exhibited significantly reduced LRE risk vs non-regressors (2.2% vs 9%; RR, 0.18; 95% CI, 0.13-0.25). Subgroup analysis in metabolic dysfunction-associated steatotic liver disease revealed similar results.
Conclusions:
Dynamic LSM changes in no-cACLD progressors and cACLD regressors are significantly associated with increased and decreased LRE risk, respectively. These findings highlight the potential of serial LSM measurements for monitoring chronic liver disease and for clinical trial endpoints. Prospective longitudinal studies are needed to evaluate if changes in LSM measurements over time are linked to improved patient outcomes.
More Related Videos
06:09Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
Published on: July 21, 2023
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:09Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...